Comorbidities in pediatric alopecia areata

Area of Science:

• Dermatology
• Pediatrics
• Genetics

Background:

• Comorbidities in pediatric alopecia areata (AA) are linked to increased healthcare costs and poorer health outcomes.
• Identifying and treating comorbidities in children with AA can improve their overall health.
• Alopecia areata is an autoimmune condition that can affect children.

Purpose of the Study:

• To determine the prevalence of comorbidities in pediatric patients diagnosed with alopecia areata.
• Utilize a large, de-identified aggregated patient database for comprehensive analysis.
• Compare comorbidity rates in children with and without alopecia areata.

Main Methods:

• Cross-sectional study design utilizing aggregated health record data up to April 1, 2019.
• Inclusion criteria: Patients ≤18 years of age.
• Comparison groups: 3510 pediatric patients with alopecia areata (AA) and 8,310,710 control patients without AA.

Main Results:

• Children with AA showed significantly higher prevalence of atopic dermatitis (17.4% vs 2.2%), anemia (7.7% vs 2.4%), obesity (5.7% vs 1.1%), vitamin D deficiency (5.1% vs 0.4%), hypothyroidism (2.6% vs 0.2%), vitiligo (1.4% vs 0.04%), psoriasis (1.4% vs 0.07%), hyperlipidemia (1.4% vs 0.2%), and depression (2.6% vs 0.6%).
• Odds ratios (OR) for these comorbidities ranged from 3.4 (anemia) to 32.2 (vitiligo), with all P values < 0.001.
• Vitiligo, psoriasis, and vitamin D deficiency showed particularly high odds ratios, indicating a strong association with pediatric AA.

Conclusions:

• Pediatric patients with alopecia areata exhibit a substantial burden of associated autoimmune and metabolic diseases.
• Children diagnosed with AA are more prone to specific autoimmune and metabolic conditions compared to the general pediatric population.
• Dermatologists should consider a multidisciplinary approach for managing pediatric AA patients due to the high prevalence of comorbidities.